Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

Trial Profile

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms TAC3A5
  • Most Recent Events

    • 28 Feb 2018 The Initial tacrolimus dosage has been changed from 0.3 mg/kg/day to 0.2 mg/kg/day (Expressers) and 0.1 mg/kg/day (for non-expressers)
    • 28 Feb 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
    • 28 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top